Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination - 21/08/11
, Kristine Breuer, MD b, Michael Meurer, MD c, Jean-Paul Ortonne, MD d, Paul C. Potter, MD e, Yves de Prost, MD f, Miles J. Davidson, MD g, Nathalie Barbier, MSc h, Hans-Peter Goertz, MPH h, Carle Paul, MD h
Reprint requests: Kim A. Papp, MD, PhD, FRCP, Probity Medical Research, 135 Union St E, Waterloo, Ontario N2J 1C4, Canada.Waterloo, Ontario, Canada; Hannover and Dresden, Germany; Nice and Paris, France; Cape Town, South Africa; Sheffield, United Kingdom; and Basel, Switzerland
Abstract |
Objective |
We investigated whether treatment of atopic dermatitis with pimecrolimus cream 1% in infants affects the development of a normal antibody response to vaccinations.
Methods |
In all, 91 patients participated in a 1-year, open-label extension to a 1-year double-blind study: 76 used pimecrolimus twice daily at the first signs or symptoms of the disease until clearance for 2 years and 15 only in the second year. Serum concentrations of antibodies against tetanus, diphtheria, measles, and rubella were measured at months 18 and 24.
Results |
The seropositivity rates of 93.6% for tetanus, 88.6% for diphtheria, 88.5% for measles, and 84.4% for rubella were comparable with those reported in literature. Seropositivity was not significantly affected by the use of pimecrolimus at the time of vaccinations (± 28 days).
Conclusions |
Treatment of atopic dermatitis with pimecrolimus cream 1% in early childhood does not appear to interfere with the development of a normal immune response to vaccinations.
Le texte complet de cet article est disponible en PDF.Plan
| Sponsored by Novartis Pharma. Disclosure: Ms Barbier, Mr Goertz, and Dr Paul hold permanent positions with Novartis Pharma. Presented in abstract form at the 2003 meeting of the European Academy of Dermatology and Venereology, Barcelona, Spain, October 15-8, 2003. |
Vol 52 - N° 2
P. 247-253 - février 2005 Retour au numéro
Article précédent
- Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study
- Kim A. Papp, Thomas Werfel, Regina Fölster-Holst, Jean-Paul Ortonne, Paul C. Potter, Yves de Prost, Miles J. Davidson, Nathalie Barbier, Hans-Peter Goertz, Carle Paul
- Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions
- Sima Halevy, Arnon D. Cohen, Nili Grossman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?